title: GeneNews Limited: bringing the blood transcriptome to personalized medicine.
abstract: GeneNews Limited (TSX:GEN) is a molecular diagnostics company, uniquely positioned to deliver on the promise of personalized medicine. GeneNews has developed and patented the Sentinel Principle(®), an innovative approach to identify clinically actionable disease biomarkers from the blood transcriptome. Novel biomarker panels have been identified to address unmet clinical needs in a broad spectrum of malignancy, including those for oncology, cardiovascular, metabolic and neurological related disorders. Currently available products and services from GeneNews are: ColonSentry™, the world's first blood-based molecular test for colorectal cancer, and; the SentinelGX™ Pharmacogenomic and Companion Diagnostic BloodRNA™ services, established to effectively support pharmaceutical partners in their companion diagnostic, development efforts.
authors.affiliation: GeneNews Ltd, 2-2 East Beaver Creek Road, Richmond Hill, Ontario, L4B 2N3, Canada. dnovak@genenews.com
authors.forename: David J
authors.initials: DJ
authors.lastname: Novak
authors.forename: Gailina J
authors.initials: GJ
authors.lastname: Liew
authors.forename: Choong-Chin
authors.initials: CC
authors.lastname: Liew
mesh_terms: D015179:Colorectal Neoplasms / Q000097:blood*; D004345:Drug Industry; D006801:Humans; D057089:Pathology, Molecular; D057285:Precision Medicine; D059467:Transcriptome / Q000235:genetics